abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - Æxlishemjandi lyf - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
clarithromycin krka filmuhúðuð tafla 250 mg
krka, d.d., novo mesto - clarithromycinum inn - filmuhúðuð tafla - 250 mg
serevent innúðalyf, dreifa 25 míkróg/skammt
glaxosmithkline pharma a/s - salmeterolum xínafóat - innúðalyf, dreifa - 25 míkróg/skammt
clarithromycin krka filmuhúðuð tafla 500 mg
krka, d.d., novo mesto - clarithromycinum inn - filmuhúðuð tafla - 500 mg
niontix lyfjagas, fljótandi 100%
linde sverige ab - dinitrogenii oxidum - lyfjagas, fljótandi - 100%
livopan lyfjagas undir þrýstingi 50/50 %
linde sverige ab - dinitrogenii oxidum; oxygenium - lyfjagas undir þrýstingi - 50/50 %
atomoxetin actavis hart hylki 10 mg
actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 10 mg
atomoxetin actavis hart hylki 18 mg
actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 18 mg
atomoxetin actavis hart hylki 25 mg
actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 25 mg
atomoxetin actavis hart hylki 40 mg
actavis group ptc ehf. - atomoxetinum hýdróklóríð - hart hylki - 40 mg